Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Det nasjonale australske HCV Point-of-Care-testprogrammet – minimalt datasett

23. september 2026 oppdatert av: Kirby Institute

Det nasjonale australske HCV Point-of-Care-testingprogrammet: En observasjonskohortstudie for å evaluere bruken av Finger-stick Point-of-care Hepatitt C-testing for å forbedre diagnose og behandling av HCV-infeksjon - Minimalt datasett

The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

The advent of simple direct-acting antiviral hepatitis C (HCV) therapies with cure rates >95% is one of the greatest medical advances in decades, having led to a reversal in liver-related mortality. In Australia, treatment uptake has declined between 2016 (32,000 treated) and 2019/20 (2019: 11,500; 2020: 8,500).1 Progress towards HCV elimination has been impeded by COVID-19, affecting the delivery of national and state-based HCV strategies. Improving HCV treatment uptake to reduce disease burden is a key aim of global, national and state-based HCV strategies.2-4

Scale-up of HCV testing and treatment will be required to achieve elimination by 2030. Current diagnostic pathways require multiple visits to a practitioner reducing the proportion who receive a diagnosis. In Australia, 81% of people have had HCV antibody testing (indicates exposure), but only 47% have been HCV RNA tested (indicates active infection and the need for HCV treatment).5 Mathematical modelling suggests that HCV RNA testing needs to increase by at least 50% annually to achieve elimination in Australia by 2030.6

The Kirby Institute is an international leader in research evaluating the Xpert HCV assay (Grebely Lancet Gastro Hep 2017), having built a large network of Xpert platforms for HCV testing in needle and syringe programs, prisons, drug treatment clinics, tertiary hospitals, and Aboriginal Community Controlled Health Service. In Kirby-led research, point-of-care HCV testing interventions in needle and syringe programs and prisons have resulted in high HCV treatment uptake (70-90%). The Kirby Institute and Flinders University also have a strong track record of implementing point-of-care testing for STIs and COVID-19, providing an ideal foundation to scale-up Xpert HCV testing in Australia.

The Kirby Institute and Flinders University will establish the Australian National HCV Point-of-care Testing Program for the scale-up of point-of-care HCV RNA testing in services with high prevalence of HCV infection, including community health centres, drug treatment clinics, needle and syringe programs, and prisons. This program will include the development of standard operating procedures, logistics/deployment, initial set-up, an operator training program, and quality assurance and competency assessment program.

An observational cohort study will be established to evaluate HCV treatment uptake following scale-up of point-of-care HCV testing among people with a risk factor for acquisition of HCV infection or people attending a service caring for people with risk factors for the acquisition of HCV infection.

Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection. All participants who undergo point-of-care HCV testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care for any other clinical assessments and treatment initiation.

Studietype

Observasjonsmessig

Registrering (Antatt)

80000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • New South Wales
      • Sydney, New South Wales, Australia
        • Aktiv, ikke rekrutterende
        • Justice Health and Forensic Mental Health Network
    • Queensland
      • Aldershot, Queensland, Australia, 4650
      • Brisbane, Queensland, Australia, 4000
        • Rekruttering
        • QuIHN
        • Ta kontakt med:
      • Cairns, Queensland, Australia
        • Rekruttering
        • Lotus Glen Correctional Centre
        • Ta kontakt med:
          • Darren Russell
        • Hovedetterforsker:
          • Darren Russell
      • Coorparoo, Queensland, Australia, 4151
        • Fullført
        • Hepatitis Queensland
      • Ipswich, Queensland, Australia
        • Rekruttering
        • West Moreton Hospital and Health Service
        • Ta kontakt med:
          • Blake Ponting
        • Hovedetterforsker:
          • Blake Ponting
      • Rathdowney, Queensland, Australia, 4287
      • Townsville, Queensland, Australia
        • Rekruttering
        • Townsville Correctional Centre
        • Ta kontakt med:
          • John Morey
        • Hovedetterforsker:
          • John Morey
      • Woodford, Queensland, Australia
        • Rekruttering
        • Woodford Correctional Centre
        • Ta kontakt med:
          • Rajendra Prakash
        • Hovedetterforsker:
          • Rajendra Prakash
    • South Australia
      • Hackney, South Australia, Australia, 5069
        • Rekruttering
        • Hepatitis SA
        • Ta kontakt med:
      • Marden, South Australia, Australia, 5070
        • Har ikke rekruttert ennå
        • South Australian Prison Health Service
        • Ta kontakt med:
          • Tom Turnbull
        • Hovedetterforsker:
          • Tom Turnbull
      • Mount Gambier, South Australia, Australia, 5290
        • Rekruttering
        • Mount Gambier Priosn
        • Ta kontakt med:
          • William Galloway
        • Hovedetterforsker:
          • William Galloway
    • Victoria
      • Fitzroy, Victoria, Australia, 3065
        • Aktiv, ikke rekrutterende
        • St Vincent's Correctional Health Services
      • Melbourne, Victoria, Australia, 3000
        • Rekruttering
        • Medically Supervised Injecting Room
        • Ta kontakt med:
          • Nathan Stam
        • Hovedetterforsker:
          • Nathan Stam
      • Ravenhall, Victoria, Australia, 3023
        • Rekruttering
        • Dame Phyllis Frost Centre
        • Ta kontakt med:
      • Ravenhall, Victoria, Australia, 3023
        • Rekruttering
        • Geo Healthcare - The Geo Group Australia Pty Ltd
        • Ta kontakt med:
          • David Grace
        • Hovedetterforsker:
          • David Grace

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.

Beskrivelse

Inclusion Criteria:

  • ≥ 18 years of age.
  • Received point-of-care HCV testing.

Exclusion Criteria:

  • Nil

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
People at risk of HCV acquisition

Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing.

Participants will be offered finger-stick point-of-care testing for HCV

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The proportion of HCV infected participants who initiate HCV treatment at 12 weeks
Tidsramme: 12 Weeks from enrolment

To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing.

12 Weeks from enrolment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The proportion of participants who accept point-of-care testing
Tidsramme: 2 years from recruitment commencement

To evaluate the proportion of people who accept point-of-care testing among those offered testing.

2 years from recruitment commencement
The prevalence of HCV infection amongst study participants tested
Tidsramme: 2 years from recruitment commencement

To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested.

2 years from recruitment commencement
To evaluate the time to HCV treatment uptake among HCV RNA positive participants
Tidsramme: 52 weeks

To evaluate the length of time participants take to initiate HCV treatment after diagnosis

52 weeks
To evaluate proportion of HCV RNA positive participants who initiate HCV treatment
Tidsramme: 52 weeks

To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.

52 weeks
To evaluate the proportion of participants who complete HCV (DAA) treatment
Tidsramme: 52 weeks

To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment.

52 weeks
To evaluate the proportion of participants who achieve an SVR
Tidsramme: 12 weeks

To evaluate the proportion of participants who achieve an SVR (defined as HCV RNA below the lower limit of quantitation at post treatment week 12).

12 weeks
To evaluate the proportion of participants who are HCV RNA negative at 12 months
Tidsramme: 52 weeks

To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing.

52 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. januar 2023

Primær fullføring (Antatt)

1. desember 2029

Studiet fullført (Antatt)

1. desember 2029

Datoer for studieregistrering

Først innsendt

12. desember 2021

Først innsendt som oppfylte QC-kriteriene

9. februar 2022

Først lagt ut (Faktiske)

21. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

Request to share IPD will be considered by the protocol steering committee on individual basis

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere